Mild cognitive impairment/Alzheimer's disease

1. Urinary β-amyloid predicts mild cognitive impairment/Alzheimer's disease in humans (multicenter case-control study) (Kappa 0.669; positive rate 72.46% in MCI/AD vs 7.52% healthy and 12.23% non-AD).

   “with a Kappa value of 0.669, indicating that the method performed well in the clinical diagnosis of MCI/AD, consistent with previously published results”

   Humansmulticenter case-control studyn = 898

   Real-World Performance of Urine β-amyloid Test Kits in Multiple Hospital Clinics and Neighborhood Communities of China

   medRxiv·May 15, 2026Preprint

More on Urinary β-amyloid

1. Vascular risk index is associated with mild cognitive impairment/Alzheimer's disease in humans (1.5-fold, p = 0.05).

   “A higher VRI was significantly associated with MCI/AD (1.5-fold, p = 0.05), FTD (1.7-fold, p =0 .02), and CVD (2.6-fold, p < 0.005) cohorts.”

   Humans

   Association between vascular risk factors burden and neurodegenerative diseases: results from ONDRI

   Journal of neurology·May 25, 2025

More on Vascular risk index

1. Arachidonic acid/docosahexaenoic acid ratio predicts mild cognitive impairment/Alzheimer's disease in preclinical AD cohort converting within 3 years (91% accuracy).

   “Arachidonic acid and DHA containing PL species, ε4-status and Aβ42/Aβ40 ratios provided 91% accuracy in detecting MCI/AD.”

   Humansin preclinical AD cohort converting within 3 yearsn = 195

   APOE ε4 specific imbalance of arachidonic acid and docosahexaenoic acid in serum phospholipids identifies individuals with preclinical Mild Cognitive Impairment/Alzheimer's Disease

   Aging·Mar 23, 2017

More on Arachidonic acid/docosahexaenoic acid ratio